Selective decrease of serum immunoglobulin G1 as marker for early stages of invasive breast cancer

Area of Science:

• Immunology
• Oncology
• Biochemistry

Background:

• Immunoglobulin G1 (IgG1) plays a role in immune responses.
• Alterations in IgG subclasses may indicate disease states.
• Accurate early detection of breast cancer is crucial for patient outcomes.

Purpose of the Study:

• To evaluate the diagnostic utility of the percentage of immunoglobulin G1 (%IgG1) in serum for breast cancer detection.
• To assess the performance of %IgG1 as a biomarker, particularly in early tumor stages.
• To correlate %IgG1 levels with tumor characteristics.

Main Methods:

• Quantitative affinity chromatography was used to measure serum IgG1 and total IgG.
• Serum samples were analyzed from 801 individuals: 174 healthy controls, 324 patients with benign breast disease, and 303 with breast cancer.
• Statistical analysis compared %IgG1 values among groups and correlated them with tumor size, stage, grade, and receptor status.

Main Results:

• Mean %IgG1 was significantly lower in breast cancer patients (52.37%) compared to healthy individuals (63.3%) and those with benign breast disease (57.75%).
• Sensitivity and specificity for distinguishing breast cancer from healthy controls were 75% and 87%, respectively.
• Sensitivity and specificity for distinguishing breast cancer from benign breast disease were 62% and 63%, respectively. A decrease in %IgG1 effectively identified tumors >5 mm.

Conclusions:

• A reduced %IgG1 in serum is a significant indicator for distinguishing breast cancer patients from healthy individuals and those with benign breast conditions.
• %IgG1 shows diagnostic potential for early-stage breast cancer detection.
• Further investigation into %IgG1's predictive capabilities at specific concentration thresholds is warranted.